Market capitalization | $2.53b |
Enterprise Value | $2.54b |
P/E (TTM) P/E ratio | 109.24 |
EV/FCF (TTM) EV/FCF | 23.39 |
EV/Sales (TTM) EV/Sales | 2.05 |
P/S ratio (TTM) P/S ratio | 2.04 |
P/B ratio (TTM) P/B ratio | 1.93 |
Revenue growth (TTM) Revenue growth | 10.69% |
Revenue (TTM) Revenue | $1.24b |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
9 Analysts have issued a Livanova PLC forecast:
9 Analysts have issued a Livanova PLC forecast:
Sep '24 |
+/-
%
|
||
Revenue | 1,238 1,238 |
11%
11%
|
|
Gross Profit | 844 844 |
10%
10%
|
|
EBITDA | 192 192 |
34%
34%
|
EBIT (Operating Income) EBIT | 137 137 |
66%
66%
|
Net Profit | 24 24 |
720%
720%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
LivaNova Plc is a global medical technology company, which engages in the development and delivery of important therapeutic solutions for the benefit of patients, healthcare professionals and healthcare systems. It operates through the following segments: Cardiovascular and Neuromodulation. The Cardiovascular segment develops, produces, and sells cardiopulmonary products, heart valves, and advanced circulatory support products. The Neuromodulation segment designs and markets NM-based medical devices for the treatment of epilepsy, depression, and obstructive sleep apnea. The company was founded on February 20, 2015 and is headquartered in London, the United Kingdom.
Head office | United Kingdom |
CEO | Vladimir Makatsaria |
Employees | 2,900 |
Founded | 1987 |
Website | www.livanova.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.